Femtech Never Measured a Hormone. Germany Just Put €40 Million Into Fixing That

Eight teams, four hormones, seven days, and one rule that disqualifies almost every wearable on the market. The woman who coined the word femtech is running it.

The rules of the SPRIND Continuous Hormone Monitoring Challenge run to a few technical requirements. Teams must directly measure at least four hormones from a panel including estrogen, progesterone, LH, FSH, testosterone and cortisol.

Continuously. Over at least seven consecutive days. In a biological matrix, meaning interstitial fluid, sweat or saliva.

Proxy signals like heart rate and skin temperature do not qualify.

Every ring, watch and app currently sold on the promise of hormonal insight is inferring from temperature, pulse and self-reported symptoms. None of them touch a hormone.

The €40 million challenge is run by Germany's Federal Agency for Breakthrough Innovation. It is directed by Ida Tin, who coined the term femtech and founded Clue, an app with more than 100 million downloads across 190 countries.

Continuous glucose monitoring works because glucose is abundant. Blood glucose sits in the millimolar range. Estradiol in human sweat sits at a few picomolar. That is a difference on the order of a billionfold.

Glucose sensors also work enzymatically, which only functions for biomarkers that happen to be enzyme substrates. Hormones are not, so measuring them continuously requires affinity-based detection, aptamers standing in for antibodies, plus solutions for biofouling, calibration drift and signal reversibility over days of wear.

Until recently, continuous real-time in vivo sensing existed for a handful of analytes. Glucose. Lactate. Blood oxygen. Early affinity biosensors topped out in the high nanomolar range, several orders of magnitude short of where reproductive hormones live.

So the sensor did not exist.

The category built what could be built, which was the interface, and sold it well.

The sensor was never a venture-shaped problem either. A subscription app compounds inside a fund's life. A picomolar-sensitive multi-hormone biosensor is a decade of materials science with a regulatory pathway at the end and no obvious subscription attached. Those are different instruments, and only one of them fits a ten-year fund.

The eight teams were chosen from 68 applicants by a jury convened at SPRIND headquarters in Leipzig. Each receives up to €1.5 million in Stage 1 as a pre-commercial research and development contract.

They are not converging on one approach. MoleSense, an EPFL spin-off, is building a needle-free sweat platform pairing low-power sweat extraction with aptamer-based nanobiosensing, contracted to measure four hormones within twelve months. Impli, with IP out of Imperial College London and a base in Lausanne, is building a minimally invasive needle-based device tracking reproductive and metabolic hormones over a multi-day wear period, aimed specifically at diagnosis in polyendocrine metabolic ovarian syndrome. Kāhu SiliconBio is working on living biosensors. Another team is building a long-lasting implantable multi-hormone sensor. Level Zero Health is on the list.

Patches, wearables, implants and engineered organisms, funded simultaneously.

They are betting not on a horse, but on the race.

And what SPRIND is buying is not a winning device. Each team must demonstrate a women's health use case where continuous data supports a clinical decision that single-point measurement cannot. The stated goal is shared scientific infrastructure, including the first standardized hormone dataset.

That dataset is the actual asset. No single startup could build it, because building it requires many sensors, many subjects, many days, and a reason to share the results with competitors. It is a public good, which is why it took a public agency.

Compare that to what exists now. A hormone is measured as a single blood draw, at one moment, usually timed to a cycle day that assumes a regular cycle. Everything about how hormones actually behave, the daily rhythm, the response to sleep and stress, the shape of the perimenopausal decline, is invisible to that method.

The tracking layer and the measurement layer are not the same business, and only one of them has been funded.

Inference supports a consumer subscription and a wellness claim. Direct measurement supports a diagnostic, a label, a payer conversation, and a clinical trial endpoint. The first layer has real users and real revenue.

The second has, until this year, mostly not existed, because the physics was not ready and the funding model did not fit.

Both of those constraints just changed.